The COVID-19 pandemic threatens to reverse recent progress in reducing the global burden of tuberculosis. The global number of deaths for tuberculosis could increase by around 200.000–400.000 in 2020 alone, as result of essential tuberculosis services disruptions due to the reallocation of human, financial and other resources from tuberculosis to the COVID-19 response, as reported by WHO: https://bit.ly/35KyzD
R-Evolution Worldwide had the exciting opportunity to collaborate with a great team of rappresentatives from the Ministries of Health of Benin and Togo in the research project proposal: “Impact of
In a Controlled Human Infection Model (CHIM) study, a well-characterised strain of an infectious agent is given to carefully selected adult volunteers in order to better understand human diseases, how they spread, and
Ebola vaccine candidates are currently being evaluated in phase I–III clinical trials conducted in Africa, the EU and the US. Although preclinical development of candidate vaccines utilise different platforms, including